Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gonadorelin Acetate

FDA-approved product (injectable, injection), marketed as Lutrepulse Kit, Factrel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gonadorelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Gonadorelin Acetate. Its therapeutic class is shown instead.

WHO therapeutic group
Gonadotropin-releasing hormones; Tests for fertility disturbances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gonadorelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gonadorelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

    NCT00500110 · start 2003-06

    Registered record
    Registry ID
    NCT00500110
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Imatinib Mesylate; Leuprolide; Goserelin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2010-02
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Imatinib Mesylate; Leuprolide; Goserelin Acetate
    PhasePhase 2
    Registry statusCompleted

  • ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

    NCT00063310 · start 2003-03

    Registered record
    Registry ID
    NCT00063310
    Conditions
    Alzheimer Disease
    Interventions
    Leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2006-02
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionLeuprolide acetate
    PhasePhase 2
    Registry statusCompleted

  • Lupron Sex Offender Therapy

    NCT00220350 · start 2001-10

    Registered record
    Registry ID
    NCT00220350
    Conditions
    Pedophilia
    Interventions
    leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2001-10
    Completion
    2005-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPedophilia
    Interventionleuprolide acetate
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

    NCT00031850 · start 2000-03

    Registered record
    Registry ID
    NCT00031850
    Conditions
    Breast Cancer
    Interventions
    goserelin acetate; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-03
    Completion
    2007-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiongoserelin acetate; raloxifene
    PhaseNot applicable
    Registry statusCompleted

  • A Treatment Study for Premenstrual Syndrome (PMS)

    NCT00001259 · start 1992-08-11

    Registered record
    Registry ID
    NCT00001259
    Conditions
    Premenstrual Syndrome; Menstruation Disturbances
    Interventions
    Leuprolide; Estradiol Patches; Progesterone; Placebo patch; Placebo injection; Placebo suppository
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1992-08-11
    Completion
    2020-02-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Syndrome; Menstruation Disturbances
    InterventionLeuprolide; Estradiol Patches; Progesterone; Placebo patch +2 more
    PhasePhase 1
    Registry statusCompleted